These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38492995)

  • 1. Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma.
    Huang X; Anderson SA; Siegal GP; Wei S; Liu S; Yang J; Roisin P; Pickens JT; Huo L; Sahin AA; Granada CP; Chen S
    Clin Breast Cancer; 2024 Jun; 24(4):e310-e318. PubMed ID: 38492995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
    Guo H; Ding Q; Gong Y; Gilcrease MZ; Zhao M; Zhao J; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
    Breast Cancer Res; 2020 Jun; 22(1):69. PubMed ID: 32576238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma.
    Hoda RS; Brogi E; Dos Anjos CH; Grabenstetter A; Ventura K; Patil S; Selenica P; Weigelt B; Reis-Filho JS; Traina T; Robson M; Norton L; Wen HY
    Mod Pathol; 2020 Nov; 33(11):2221-2232. PubMed ID: 32612248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
    Sigurjonsdottir G; De Marchi T; Ehinger A; Hartman J; Bosch A; Staaf J; Killander F; Niméus E
    Breast Cancer Res; 2023 Oct; 25(1):123. PubMed ID: 37817263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.
    Miyakoshi J; Yazaki S; Shimoi T; Onishi M; Saito A; Kita S; Yamamoto K; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Fujiwara Y; Yoshida M; Yonemori K
    Virchows Arch; 2023 Dec; 483(6):855-863. PubMed ID: 37668667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
    Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
    Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
    Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N
    Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma.
    Hoffmann LG; Sarian LO; Vassallo J; de Paiva Silva GR; Ramalho SOB; Ferracini AC; da Silva Araujo K; Jales RM; Figueira DE; Derchain S
    Sci Rep; 2021 Nov; 11(1):22478. PubMed ID: 34795307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates.
    Pournabee M; Keshavarz-Fathi M; Esmaeili P; Mahdavi Sharif P; Nili F; Jahanbin B
    BMC Cancer; 2023 Jun; 23(1):495. PubMed ID: 37264298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.
    Danziger N; Sokol ES; Graf RP; Hiemenz MC; Maule J; Parimi V; Palmieri C; Pusztai L; Ross JS; Huang RSP
    Oncologist; 2023 Apr; 28(4):319-326. PubMed ID: 36866462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
    Huang X; Ding Q; Guo H; Gong Y; Zhao J; Zhao M; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
    Hum Pathol; 2021 Feb; 108():42-50. PubMed ID: 33221342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
    Loibl S; Untch M; Burchardi N; Huober J; Sinn BV; Blohmer JU; Grischke EM; Furlanetto J; Tesch H; Hanusch C; Engels K; Rezai M; Jackisch C; Schmitt WD; von Minckwitz G; Thomalla J; Kümmel S; Rautenberg B; Fasching PA; Weber K; Rhiem K; Denkert C; Schneeweiss A
    Ann Oncol; 2019 Aug; 30(8):1279-1288. PubMed ID: 31095287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
    BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy.
    Alhesa A; Awad H; Bloukh S; Al-Balas M; El-Sadoni M; Qattan D; Azab B; Saleh T
    Int J Immunopathol Pharmacol; 2022; 36():3946320221078433. PubMed ID: 35225058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes.
    Ni Y; Tsang JY; Shao Y; Poon IK; Tam F; Shea KH; Tse GM
    Oncologist; 2022 Apr; 27(4):e313-e327. PubMed ID: 35380716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
    Al-Jussani GN; Dabbagh TZ; Al-Rimawi D; Sughayer MA
    Ann Diagn Pathol; 2021 Apr; 51():151703. PubMed ID: 33454500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.